Executive Team

Francis E. O’Donnell Jr., M.D.
Executive Chairman
Dr. O’Donnell has been a Director and Vice-Chairman of Biovest since June 2003.  In February 2009, Dr. O’Donnell was appointed as Chairman & Chief Executive Officer.  Since 2002, Dr. O’Donnell has served as the Chairman & CEO of Accentia Biopharmaceuticals, Inc., Biovest’s parent corporation.  He is also the Chairman of BioDelivery Sciences International, Inc. (NASDAQ: “BDSI”), a publicly-traded drug delivery company.  Dr. O’Donnell is the Founder and Manager of The Hopkins Capital Group (“HCG”), an affiliation of limited liability companies which engage in business development and venture investment activities for novel healthcare technologies, with certain HCG entities being significant stockholders in Biovest, Accentia and BioDelivery Sciences.  Dr. O’Donnell is a 1975 summa cum laude graduate of the Johns Hopkins School of Medicine.  He received his specialty training at the Wilmer Ophthalmological Institute, Johns Hopkins Hospital.  He is the former Professor and Chairman, Department of Ophthalmology, St. Louis University School of Medicine.  Dr. O’Donnell has published over 30 peer-reviewed scientific articles and he has been awarded over 34 U.S. Patents.  He is the recipient of the 2000 Jules Stein Award from Retinitis Pigmentosa International. He is a Trustee for St. Louis University.

Samuel S. Duffey, Esq.
CEO, President & General Counsel
Mr. Duffey was named Biovest’s President in December 2008, and he has also served as our General Counsel since April 2003.  Prior to that, Mr. Duffey practiced business law with Duffey & Dolan P.A. beginning in 1992.  From February 2000 to September 2003, Mr. Duffey served as the non-executive Chairman and as a Member of the Board of Directors of Invisa, Inc., a small publicly-held safety company, and from October 2001 to May 2004, Mr. Duffey also served as the non-executive Chairman and as a Member of the Board of Directors of FlashPoint International, Inc., a publicly-held automotive parts company which is currently named Navitrak International Corporation.  Mr. Duffey received his B.A. and J.D. degrees from Drake University.

Brian D. Bottjer
Acting Chief Financial Officer
Mr. Bottjer has served as Biovest’s Controller since June 2007, and was named Acting Chief Financial Officer in January 2011.  From September 2006 to May 2007, Mr. Bottjer was our Senior Accountant.  Prior to that time, from August 2005 to August 2006, Mr. Bottjer was employed as a Controller for Stewart Title Guaranty Company, a provider of title insurance and related services to the real estate and mortgage industries.  From March 2003 to August 2005, Mr. Bottjer served at Raymond James & Associates, Inc., a full service brokerage firm headquartered in St. Petersburg, Florida in a number of roles, including that of manager of financial reporting for certain of the company’s business units.  Mr. Bottjer has also served in a variety of financial reporting and administrative roles at the Home Shopping Network and Allstate Insurance Corporation. Mr. Bottjer is a licensed Certified Public Accountant and received his B.S. in business administration from the State University of New York at Buffalo in 1997.

Carlos F. Santos, Ph.D.
Senior Vice President, Product Development & Regulatory Affairs
Dr. Santos manages responsibilties related pharmaceutical product development, intellectual property design, regulatory strategy and corporate development planning activities for Biovest.  Dr. Santos also serves as Chief Science Officer for Biovest’s parent, Accentia Biopharmaceuticals, Inc., and holds the same role with Hopkins Capital Group, contributing to its portfolio of companies since 1998.   Dr. Santos is a graduate of the University of Michigan where he earned a Ph.D. in Bioinformatics, and Washington University (St. Louis) where he earned a B.S. in Computer Science.  At the University of Michigan, he developed automated natural language processing systems to integrate high-throughput genomic experimental data with known protein interaction pathways in metastatic prostate cancer progression.  He also led the development of an large-scale automated search and summarization engines for biomedical documents at the University of Michigan’s National Center for Integrative Biomedical Informatics (NCIBI).  And from 1998-2001, he was a researcher at Washington University’s Institute for Biomedical Computing (now the Center for Computational Biology).

Mark Hirschel, Ph.D.
Chief Scientific Officer
Named Chief Scientific Officer in September 2001, Dr. Hirschel directs all of Biovest’s activities related to instruments and cell culture production & services, including validated commercial production of BiovaxID, and managing Biovest’s 35,000 sq. ft. bio-manufacturing facility in Minneapolis.  Prior to being named CSO, he served as Senior Vice President.  As a recognized leader in cell culture production, with a specialty expertise in hollow-fiber systems, Dr. Hirschel served as the Principal Investigator of the National Cell Culture Center at Biovest, producing and delivering more than 1000 cell lines and therapeutic proteins to the National Institutes of Health (NIH) over a 16-year period.   Dr. Hirschel has authored numerous scientific publications, has received several grants and has served on several NIH committees.  Dr. Hirschel holds a B.A. in Biology from Southwest State University (MN), an M.S. in Animal Physiology, and a Ph.D. in Reproductive Physiology from the University of Minnesota.

Douglas W. Calder
Vice President, Strategic Planning & Capital Markets
Mr. Calder brings more than 18-years of life science executive experience as a financial portfolio manager and investor relations professional in managing corporate communications, business development, media strategies and capital markets responsibilities for Biovest and its parent, Accentia Biopharmaceuticals, Inc.  Prior to joining Biovest, Mr. Calder served for 8-years as Investor Relations Officer for Viragen, Inc., an AMEX-listed, publicly-traded biotechnology company.  Prior to Viragen, he spent nearly 10-years as financial portfolio manager with a biotechnology focus working for the New York Stock Exchange Member Firms: Dean Witter Reynolds; Gruntal & Co.; and Moors & Cabot.  Mr. Calder received his B.A. from Florida State University.

David D. Moser
Director of Legal Affairs & Corporate Secretary
Mr. Moser has served as Biovest’s Director of Legal Affairs since January 2000 and has served as our Secretary since December 31, 2007.  Mr. Moser’s educational background includes a B.A. in Political Science (cum laude, Phi Beta Kappa) from Columbia University and a J.D. (cum laude) from Harvard Law School.  Prior to joining the Company, Mr. Moser was involved in general business, corporate and real estate litigation practice and engaged in residential and commercial real estate brokerage.

Board of Directors

• Francis E. O’Donnell Jr., M.D. (Chairman)
• Ronald Osman, Esq.
• Edmund C. King
• Christopher C. Chapman, M.D.
• Raphael J. Mannino, Ph.D.
• Peter J. Pappas, Sr.
• Jeffrey A. Scott, M.D.
• John Sitilides